Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Next Previous
Trial Profile

A Multicenter Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bosutinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms BFORE
  • Sponsors Avillion; Pfizer

Most Recent Events

  • 15 Jun 2023 Results of post-hoc pooled analysis of B1871006 (NCT00261846), B1871007 (NCT00811070), B1871039 (NCT02228382, BYOND) B1871048 (NCT03128411), B1871008 (NCT00574873) & (B1871040, NCT01903733) assessing effect of BMI on the safety of bosutinib in patients with previously treated or newly diagnosed CML, presented at the 28th Congress of the European Haematology Association.
  • 13 Dec 2022 Results assessing the impact of comorbidities on efficacy and safet of Bosutinib reporting the results by Charlson Comorbidity Index (CCI)after 5 years of follow up, presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Results assessing the efficacy and safety (after 5-Years Follow-up) of bosutinib versus imatinib after 5-years follow-up in a subpopulation of US patients, presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top